The present announcement does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In the interests of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process designation "open process" (Section IV.1.1) used in the context of the present announcement text is owed to the specifications of the announcement form. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is by law or procurement ordinances is not mandatory. It is a framework agreement with the option to join, which relates to various active ingredients.

The subject of the contract are drugs that contain the active ingredient combination abacavir and lamivudine and zidovudine.

The subject of the contract are drugs that contain the active ingredient etravirine.

The subject of the contract are drugs that contain the active ingredient filgrastim.

The subject of the contract are drugs that contain the active ingredient fosamprenavir.

The subject of the contract are drugs that contain the active ingredient human papillomavirus vaccine.

The subject of the contract are drugs that contain the active ingredient combination ipratropium and fenoterol.

The subject of the contract are drugs that contain the active ingredient isosorbide dinitrate.

The subject of the contract are drugs that contain the active ingredient levofloxacin (parenteral).

The subject of the contract are drugs that contain the active ingredient Milnacipran.

The subject of the contract are drugs that contain the active ingredient pantoprazole (parenteral).

The subject of the contract are drugs that contain the active ingredient PEG-epoetin beta.

The subject of the contract are drugs that contain the active ingredient acemetacin (HKP).

The subject of the contract are drugs that contain the active ingredient pegfilgrastim.

The subject of the contract are drugs that contain the active ingredient peginterferon alfa-2a.

The subject of the contract are drugs that contain the active ingredient trastuzumab 150 mg.

The subject of the contract are drugs that contain the active ingredient trastuzumab 600 mg.

The subject of the contract are drugs that contain the active ingredient vedolizumab.

The subject of the contract are drugs that contain the active ingredient acemetacin (REK).

The subject of the contract are drugs that contain the active ingredient clobetasol.

The subject of the contract are drugs that contain the active ingredient combination dolutegravir and abacavir and lamivudine.

The subject of the contract are drugs that contain the active ingredient emtricitabine.

The subject of the contract are drugs that contain the active ingredient enoxaparin sodium (20 mg, 40 mg).

The subject of the contract are drugs that contain the active ingredient enoxaparin sodium (60 mg, 80 mg, 100 mg).

The subject of the contract are drugs that contain the active ingredient esomeprazole (parenteral).